The Impact of Antiplatelet Therapy on Pelvic Fracture Outcomes
Author Information
Author(s): Christy Jonathan M Stawicki, S Peter Jarvis, Amy M Evans, David C Gerlach, Anthony T Lindsey, David E Rhoades, Peggy Whitmill, Steven M Steinberg, Laura S Phieffer, Charles H Cook
Primary Institution: The Ohio State University Medical Center
Hypothesis
Does pre-injury antiplatelet therapy affect outcomes in patients with pelvic fractures?
Conclusion
Pre-injury use of antiplatelet therapy does not significantly affect morbidity or mortality in trauma patients with pelvic fractures.
Supporting Evidence
- Patients on antiplatelet therapy were older than those not on it.
- Those on antiplatelet therapy had more comorbidities and lower hemoglobin levels.
- There was no significant difference in mortality between the two groups.
Takeaway
This study found that taking certain medications before a pelvic injury doesn't really change how well people do after the injury, but those who took them were more likely to need blood transfusions soon after.
Methodology
Retrospective review of patients over 45 years with pelvic fractures, comparing those on antiplatelet therapy to those not on it.
Potential Biases
Potential bias due to the retrospective nature and lack of control over confounding variables.
Limitations
The study has a relatively small sample size and is retrospective, limiting causal inferences.
Participant Demographics
Patients were over 45 years old, with a mix of genders and various comorbidities.
Statistical Information
P-Value
p<0.01 for age difference, p<0.05 for transfusion rates.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website